The Medalight Pharmaceuticals has a diverse research and development programme, which aims to create world-class solutions in areas of high unmet need. In 2024 our R&D investment was €7.9 million. We have a network of 32 research institutes around the world. Medalight is willing to take the long-term view when it comes to investing in researching diseases and disorders that are difficult to treat. Our portfolio is rich and varied and our freethinking attitude means that we avoid general approaches to product development. This helps us to create the healthcare solutions of tomorrow, as we search for new opportunities in our global research areas of neuroscience, oncology, cardiovascular, renal, gastroenterology, infectious diseases, ophthalmology and dermatology. We are also exploring how digital health technology may provide holistic health solutions for patients, carers and healthcare professionals..
ˀPart of a European group with over 50 years’ experience of manufacturing and supply of generic medicines. Variety of products available across a wide range of therapeutic areas. Delivers over 30 million packs annually. Exciting pipeline of new product launches. Manufactures in state of the art facilities worldwide including England, Spain, China and India. Monitors the entire supply-chain from ingredients to finished products ensuring high quality medicines are delivered on time.
With a fast-growing portfolio of prescription medicines and OTCs, coupled with a responsive high-quality supply chain, Medalight Pharmaceuticalsceuticals has the expertise to supply the right product at the right time throughout the US.
The Medalight Pharmaceuticalsceuticals has a diverse research and development programme, which aims to create world-class solutions in areas of high unmet need. In 2024 our R&D investment was €1.9 billion. We have a network of 32 research institutes around the world. Otsuka is willing to take the long-term view when it comes to investing in researching diseases and disorders that are difficult to treat.
Our portfolio is rich and varied and our freethinking attitude means that we avoid general approaches to product development. This helps us to create the healthcare solutions of tomorrow, as we search for new opportunities in our global research areas of neuroscience, oncology, cardiovascular, renal, gastroenterology, infectious diseases, ophthalmology and dermatology. We are also exploring how digital health technology may provide holistic health solutions for patients, carers and healthcare professionals. Supplies wholesalers and hospitals nationwide from a centrally located warehouse.
Our cell culture solutions support you in the development of biopharmaceutical products. Media providers and biopharma companies around the world rely on our unique combination of high-quality ingredients, expertise across chemistry and biotechnology and solid manufacturing capabilities.
The Medalight Pharmaceuticalsceuticals production network relies on decades-long manufacturing experience and an excellent degree of backward integration to ensure the highest level of quality control and the reliable supply of critical cell culture ingredients.
If you have any general questions about Otsuka Pharmaceutical Europe Ltd. or the work we do in Europe, please get in touch with us via the contact details below
Phone:
Email
